Psychopharmacology Of COVID-19 Flashcards

1
Q

Only FDA approved drug for treatment of suspected or confirmed severe COVID-19 infection

A

REMDESIVIR an antiviral that interacts w/ RNA polymerase (infusion; for 5 or 10 days)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Organs affected by COVID

A

liver, kidneys, lungs, and heart, as well as the immune and hematological systems

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

a hematologic feature of severe COVID- 19 cases and may serve as a poor prognostic factor

A

lymphopenia

lymphocyte count less than 1.0 x 109/L

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

most commonly implicated psychotropics in hematological adverse effects including leukopenia, neutropenia & agranulocytosis

A
carbamazepine and clozapine
(there is a class effect FDA warning on all 1st and 2nd generation antipsychotics)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

COVID19 patients on clozapine have a higher risk of?

A

pneumonia & its complications

Explanations include aspiration, sialorrhea, sedation, & poorly understood effects on the immune system.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What to do with Clozapine dose if patient has fever and other signs of infection?

A

Reduce the dose by up to a half; closely monitor clozapine levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

psychotropics associated w/ platelet dysfunction & increased bleeding risk?

A

SSRIs and Valproic Acid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

psychotropics of concern that can prolong QT interval

A

antipsychotics, TCAs, and the SSRI citalopram appear to be the agents of most concern

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

typical antipsychotic that causes greatest QT prolongation

A

thioridazine

IV Haloperidol also implicated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

atypical antipsychotics that cause higher risk of QT prolongation

A

ziprasidone and possibly iloperidone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

antipsychotics with lowest risk of QT prolongation

A

aripiprazole & possibly lurasidone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

psychotropics associated w/ mild hepatoxicity that manifests w/ modest, transient increases in liver enzymes

A

valproate, carbamazepine, TCAs, SNRIs and second-generation antipsychotics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

agents that are high risk of causing serious drug-induced liver injury

A

chlorpromazine, carbamazepine, valproate, duloxetine, and nefazodone (avoid in pxs w/ covid-19-associated liver dx)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Psychotropics highly dependent on renal excretion (so nephrotoxic)

A

lithium, gabapentin, topiramate, pregabalin, and paliperidone (duloxetine not recommended for those w/ severe renal impairment)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Neurologic symptoms falling into 3 categories

A
  1. CNS (headache, dizziness, ataxia, acute CVD, impaired consciousness, seizure)
  2. PNS (impairment in taste, vision, smell and neuropathic pain)
  3. Skeletal muscular injury
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Avoid these agents in patients with COVID-19 delirium since they can cause or exacerbate confusion, sedation, and/or falls

A

benzodiazepines, opioids, & drugs with strong anticholinergic properties (tertiary amine TCAs, low- potency antipsychotics, benztropine, diphenhydramine)

17
Q

psychotropics that can lower the seizure threshold in patients with seizures or structural brain lesions.

A

most antipsychotics (especially clozapine, quetiapine, olanzapine, and FGAs) and certain antidepressants (bupropion, tricyclics)

18
Q

Psychiatric side effects of Chloroquine and Hydroxychloroquine

A

Psychosis, delirium, suicidality, personality changes, depression, nervousness, irritability, compulsive impulses, preoccupations, and aggressiveness

19
Q

Higher risk of neuropsychiatric side effects when combined with CYP3A4 inhibitors, low- dose glucocorticoids, alcohol intake, family history of psychiatric disease, female gender, low body weight, and supratherapeutic dosing

A

Hydroxychloroquine

20
Q

a recombinant humanized monoclonal antibody that acts as an IL-6 receptor inhibitor and is FDA approved to treat several types of arthritis.
IL-6 appears to be involved in cytokine storms that have been observed in critically ill patients with COVID-19.

A

Tocilizumab

has possible positive effects on depressive symptoms

21
Q

Antiviral: RNA-dependent RNA polymerase inhibitor approved in China but not in the US

A

Favipiravir

mild QT prolongation in a patient with Ebola

22
Q

Psychiatric side effects: Possible abnormal dreams, agitation, anxiety, confusion, & emotional lability
All protease inhibitors associated with paresthesias, taste alterations, & neurotoxicity

A

Lopinavir/Ritonavir:

Antiviral Lopinavir: protease
inhibitor
Ritonavir: boosts plasma
levels of lopinavir

23
Q
  • Extensively metabolized by CYP450– risk of multiple possible interactions
  • Contraindicated with pimozide, midazolam, triazolam
  • Lowers concentrations of some psychotropics (bupropion, methadone, lamotrigine, & olanzapine)
  • Other SEs: SJS, DM, QTc prolongation, pancreatitis, neutropenia, hepatotoxicity, and CKD
A

Lopinavir/Ritonavir:

Antiviral Lopinavir: protease
inhibitor
Ritonavir: boosts plasma
levels of lopinavir

24
Q

What is Convalescent plasma therapy

A

Antibody containing convalescent plasma from patients who have recovered from viral infections

25
Q

Antibacterial which may have antiviral & anti-inflammatory properties
Used with hydroxychloroquine.

A

Azithromycin

26
Q

Psychiatric SEs: psychotic depression, catatonia, delirium, aggressive reaction, anxiety, dizziness, headache, vertigo, and somnolence

A

Azithromycin

(Risk of QTc prolongation, TDPs &
hepatotoxicity)

27
Q

an antioxidant and reducing agent, for treatment of sepsis because of its enhancement of the immune response and preventing progressive organ dysfunction

A

Vitamin C

Coadministration with barbiturates may decrease the effects of vitamin C

28
Q

Immune modulators and anti-inflammatory: may lessen cytokine storm and hyperinflammation syndrome

A

Corticosteroids

29
Q
  • Phenytoin—increases hepatic metabolism
  • Caution with bupropion—lowers seizure threshold
  • Majority of neuropsychiatric side effects occur early in treatment course, usually w/in days, and dosing is the most significant risk factor (ie at prednisone equivalents of .40 mg/d)
A

Corticosteroids

Depression, mania, agitation, mood lability, anxiety, insomnia, catatonia, depersonalization, delirium, dementia, and psychosis

30
Q

glycoproteins that have immunomodulatory, antiproliferative, and hormone-like activities
antiviral

A

Interferon
IFN alpha “life-threatening/ fatal neuropsychiatric disorders.” effects include fatigue, mood disorders, suicidality, anxiety disorders, irritability, lability, apathy, sleep disturbance, and cognitive deficits.
Side effects of IFN beta fatigue, weight loss, myalgia, and arthralgia

31
Q

a plant-derived alkaloid with anti-inflammatory properties that is used for rheuma and cardiac conditions.
hypothesized that it could treat COVID-19 through targeting the overactive interleukin-6 pathway.

A

Colchicine

  • has narrow therapeutic index
  • metabolized by CYP3A4 and excreted via P-glycoprotein transport system as well as cleared by the kidneys through glomerular filtration
32
Q

the gold standard for managing agitation in COVID-19 delirious patients.

A

Haloperidol
-a-2 agonists (dexmedetomidine & clonidine) or antiepileptics (valproic acid) should be considered if cardiac risk is high and/or if the antipsychotic is clinically ineffective.

33
Q

psychotropics recently named on a list of FDA-approved medications with potential for in vitro action against SARS-CoV-2

A

Haloperidol and Valproic Acid

34
Q

SSRI under investigation for its potential to reduce the inflammatory response during sepsis by inhibiting cytokine production

A

Fluvoxamine